Journal article
Tolerability of a Salmeterol Xinafoate/Fluticasone Propionate Hydrofluoroalkane Metered-Dose Inhaler in Adolescent and Adult Patients with Persistent Asthma: A 52-Week, Open-Label, Stratified, Parallel-Group, Multicenter Study
Abstract
BACKGROUND: Many patients with asthma require an inhaled long-acting beta(2)-agonist (LABA) in addition to an inhaled corticosteroid to adequately control their disease.
OBJECTIVE: The purpose of this study was to assess the long-term tolerability of a salmeterol xinafoate/ fluticasone propionate (SFC) hydrofluoroalkane metered-dose inhaler (MDI) at 3 different doses BID.
Authors
Cowie RL; Boulet L-P; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Journal
Clinical Therapeutics, Vol. 29, No. 7, pp. 1390–1402
Publisher
Elsevier
Publication Date
July 2007
DOI
10.1016/j.clinthera.2007.07.021
ISSN
0149-2918
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdrenergic beta-AgonistsAdultAgedAlbuterolAlkanesAndrostadienesAsthmaBronchodilator AgentsChildDose-Response Relationship, DrugDrug CombinationsElectrocardiographyFemaleFluticasone-Salmeterol Drug CombinationHumansHydrocortisoneMaleMetered Dose InhalersMiddle AgedRespiratory Function Tests